Comprehensive Treatment of Pancreatic Neuroendocrine Neoplasms_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIUHao ¹ ,  WUCheng-yi ² , LüZhong-zhu ¹

1. Department of General Surgery, The People's Hospital of Bishan Distrct, Chongqing 402760, China;
2. Department of endocrinology and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

Corresponding?author：

WUCheng-yi, Email: 498746093@qq.com

Keywords：

Irreversible electroporation; Tumor; Ablation

DOI：

10.7507/1007-9424.20160097

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summary the treatment of pancreatic neuroendocrine neoplasms (pNENs). Methods Articles relevant to pNENs at home and abroad were collected and reviewed. Results Because of rare incidence and non-specific clinical syndromes of pNENs, clinician had no enough cognition about it. For pNENs, surgery was still the preferred option, combining other treatments included chemotherapy, somatostatin analogue, α-interferon, molecular targeted therapy, and peptide receptor radionuclide therapy (PRRT). Conclusion Surgery is still considered as the preferred option for controlling the associated biochemical syndromes and curtailing the malignant progression of pNENs.

Citation： LIUHao, WUCheng-yi, LüZhong-zhu. Comprehensive Treatment of Pancreatic Neuroendocrine Neoplasms. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(3): 369-373. doi: 10.7507/1007-9424.20160097 Copy

1.	盛偉琪. 胃腸胰神經內分泌腫瘤病理診斷的規范和進展. 中國癌癥雜志, 2013, 23(6): 401-406.
2.	中國胃腸胰神經內分泌腫瘤病理專家組. 中國胃腸胰神經內分泌腫瘤病理學診斷共識(2013版). 中華病理學雜志, 2013, 42(10): 691-694.
3.	徐建明. 重視對胃腸胰神經內分泌腫瘤的認識. 中華腫瘤雜志, 2012, 34(2): 158-160.
4.	Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer, 2003, 97(4): 934-959.
5.	岑超平, 陳曉, 李沖, 等. 胰腺神經內分泌腫瘤診治進展. 腫瘤基礎與臨床, 2015, 28(2): 178-180.
6.	CSCO神經內分泌腫瘤專家委員會. 中國胃腸胰神經內分泌腫瘤專家共識. 臨床腫瘤學雜志, 2013, 18(9): 815-832.
7.	張太平, 熊光冰, 趙玉沛. 胰腺神經內分泌腫瘤診治進展. 中華外科雜志, 2014, 52(9): 706-708.
8.	Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 2008, 9(1): 61-72.
9.	Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
10.	Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin, 2011, 61(2): 113-132.
11.	Grobmyer SR, Vogel SB, Mcguigan JE, et al. Reoperative surgery in sporadic Zollinger-Ellison Syndrome: long-term results. J Am Coll Surg, 2009, 208(5): 718-722.
12.	Boudrcause JP. Surgery for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am, 2011, 40(1): 163-171.
13.	陳鑫, 吳誠義. 罕見胰腺內分泌腫瘤的診治. 中國普外基礎與臨床雜志, 2012, 19(10): 1039-1043.
14.	顏兆寰, 溫巧生, 王滔明, 等. 胃泌素瘤的診斷及預后. 實用醫學雜志, 2010, 26(22): 4222-4223.
15.	劉勇峰, 梅樂園, 賀愛軍, 等. 腹腔鏡胰體尾脾切除術治療胰高血糖素瘤1例報告. 腹腔鏡外科雜志, 2011, 16(5): 398-399.
16.	張正筠, 周光文, 申川, 等. 肝移植治療胰腺生長抑素瘤肝轉移一例. 中華外科雜志, 2007, 45(15): 1075-1076.
17.	Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res, 2004, 120(1): 139-161.
18.	Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol, 2004, 22(23): 4762-4771.
19.	Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab, 2009, 94(4): 1074-1080.
20.	中華醫學會外科學分會胰腺外科學組. 胰腺神經內分泌腫瘤治療指南（2014）. 中國實用外科雜志, 2014, 34(12): 1117-1119.
21.	Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol, 2010, 17(12): 3129-3136.
22.	Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol, 2012, 30(24): 2963-2968.
23.	Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
24.	Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 501-513.
25.	Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117(2): 268-275.
26.	Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 2011, 117(20): 4617-4622.
27.	Pavel ME, Wiedenman B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
28.	中華醫學會腫瘤學分會胰腺癌學組. 胰腺神經內分泌腫瘤診治專家共識. 中華腫瘤雜志, 2014, 36(9): 717-720.
29.	Oberg K, Ferone D, Kaltsas G, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology, 2009, 90(2): 209-213.
30.	梁后杰, 楊晨. 胃腸胰腺神經內分泌腫瘤治療共識(NCCN、ENETs、NANETs)解讀. 臨床腫瘤學雜志, 2011, 16(11): 1039-1043.
31.	Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 2008, 26(20): 3403-3410.
32.	Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol, 2010, 28(6): 1075-1083.
33.	Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 514-523.
34.	Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide rece-ptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med, 2010, 40(2): 78-88.
35.	劉毫, 吳誠義, 朱之坤, 等. 胰高血糖素瘤的診治現狀. 中華內分泌外科雜志, 2014, 8(3): 243-245.
36.	Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol, 2008, 26(13): 2124-2130.

1. 盛偉琪. 胃腸胰神經內分泌腫瘤病理診斷的規范和進展. 中國癌癥雜志, 2013, 23(6): 401-406.
2. 中國胃腸胰神經內分泌腫瘤病理專家組. 中國胃腸胰神經內分泌腫瘤病理學診斷共識(2013版). 中華病理學雜志, 2013, 42(10): 691-694.
3. 徐建明. 重視對胃腸胰神經內分泌腫瘤的認識. 中華腫瘤雜志, 2012, 34(2): 158-160.
4. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer, 2003, 97(4): 934-959.
5. 岑超平, 陳曉, 李沖, 等. 胰腺神經內分泌腫瘤診治進展. 腫瘤基礎與臨床, 2015, 28(2): 178-180.
6. CSCO神經內分泌腫瘤專家委員會. 中國胃腸胰神經內分泌腫瘤專家共識. 臨床腫瘤學雜志, 2013, 18(9): 815-832.
7. 張太平, 熊光冰, 趙玉沛. 胰腺神經內分泌腫瘤診治進展. 中華外科雜志, 2014, 52(9): 706-708.
8. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 2008, 9(1): 61-72.
9. Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
10. Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin, 2011, 61(2): 113-132.
11. Grobmyer SR, Vogel SB, Mcguigan JE, et al. Reoperative surgery in sporadic Zollinger-Ellison Syndrome: long-term results. J Am Coll Surg, 2009, 208(5): 718-722.
12. Boudrcause JP. Surgery for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am, 2011, 40(1): 163-171.
13. 陳鑫, 吳誠義. 罕見胰腺內分泌腫瘤的診治. 中國普外基礎與臨床雜志, 2012, 19(10): 1039-1043.
14. 顏兆寰, 溫巧生, 王滔明, 等. 胃泌素瘤的診斷及預后. 實用醫學雜志, 2010, 26(22): 4222-4223.
15. 劉勇峰, 梅樂園, 賀愛軍, 等. 腹腔鏡胰體尾脾切除術治療胰高血糖素瘤1例報告. 腹腔鏡外科雜志, 2011, 16(5): 398-399.
16. 張正筠, 周光文, 申川, 等. 肝移植治療胰腺生長抑素瘤肝轉移一例. 中華外科雜志, 2007, 45(15): 1075-1076.
17. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res, 2004, 120(1): 139-161.
18. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol, 2004, 22(23): 4762-4771.
19. Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab, 2009, 94(4): 1074-1080.
20. 中華醫學會外科學分會胰腺外科學組. 胰腺神經內分泌腫瘤治療指南（2014）. 中國實用外科雜志, 2014, 34(12): 1117-1119.
21. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol, 2010, 17(12): 3129-3136.
22. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol, 2012, 30(24): 2963-2968.
23. Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
24. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 501-513.
25. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117(2): 268-275.
26. Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 2011, 117(20): 4617-4622.
27. Pavel ME, Wiedenman B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
28. 中華醫學會腫瘤學分會胰腺癌學組. 胰腺神經內分泌腫瘤診治專家共識. 中華腫瘤雜志, 2014, 36(9): 717-720.
29. Oberg K, Ferone D, Kaltsas G, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology, 2009, 90(2): 209-213.
30. 梁后杰, 楊晨. 胃腸胰腺神經內分泌腫瘤治療共識(NCCN、ENETs、NANETs)解讀. 臨床腫瘤學雜志, 2011, 16(11): 1039-1043.
31. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 2008, 26(20): 3403-3410.
32. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol, 2010, 28(6): 1075-1083.
33. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 514-523.
34. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide rece-ptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med, 2010, 40(2): 78-88.
35. 劉毫, 吳誠義, 朱之坤, 等. 胰高血糖素瘤的診治現狀. 中華內分泌外科雜志, 2014, 8(3): 243-245.
36. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol, 2008, 26(13): 2124-2130.

Previous Article
A New and Minimally Invasive Ablation Technology for Tumors——Irreversible Electro-poration
Next Article
Application of Tranexamic Acid in Patients with Trauma-Related Hemorrhage

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Comprehensive Treatment of Pancreatic Neuroendocrine Neoplasms

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content